Invited Faculty
  • Stephen Oliver
    Novartis AG
  • Stephen Oliver has received board certifications in internal medicine and in rheumatology and has membership in the American College of Rheumatology and in the American Association of Immunologists. His academic training includes a rheumatology fellowship at UCLA Medical Center under Bevra Hahn, followed by additional training in clinical and laboratory research while based at The Rockefeller University, New York City (Mentor, Gilla Kaplan; Lab head, Ralph Steinman). Steve established a laboratory within New York University-Bellevue Hospital while an assistant professor of medicine within the division of clinical pharmacology, headed by Bruce Cronstein. During this time, Steve was the primary investigator in NIH-sponsored clinical and laboratory studies in scleroderma and in sarcoidosis, as well as co-primary investigator in an NIH grant to study the effects of perceived stress on immunity. In 2009, Steve moved to Basel, Switzerland to take on the role of senior translational medicine expert for Novartis Pharma AG where he conducted early phase clinical trials across a range of autoimmune and inflammatory conditions. In addition, he led the clinical development of ianalumab (VAY736) into first-in-human studies that included patients with rheumatoid arthritis, and initial ph2 studies in Sjögren’s syndrome and systemic lupus erythematosus. Currently, Steve is the global program clinical head for ianalumab phase 3 development in its lupus indications.
    Research & Clinical Focus

    Clinical drug Development



    Systemic lupus erythematosus

    Lupus nephritis

  • Date Time Room Session Title Lecture Title
    May 20 08:00-08:40 Room Grand Ballroom 101+102 [Breakfast Symposium 9 - Novartis] Breakfast Symposium 9 Evolution of therapeutic B cell depletion in lupus